Novavax has begun a big late-stage research of its experimental Covid-19 vaccine in the United States, the drug developer mentioned on Monday, after delaying the trial twice because of points in scaling up the manufacturing course of.
It will enroll as much as 30,000 volunteers throughout about 115 websites in the United States and Mexico, with two-thirds of them receiving the shot 21 days aside and the remaining getting placebo, the corporate mentioned.
Novavax lags behind different drugmakers in the worldwide race for Covid-19 vaccines, with pictures from Pfizer and Moderna licensed for emergency use in the United States.
But consultants have mentioned multiple vaccine could be wanted to finish the pandemic that has killed over 1.7 million folks globally.
Novavax has signed provide agreements with a number of international locations and is ready to supply 60 million doses to the U.Ok., the place a late-stage research is underway. The interim knowledge from the trial is predicted in the primary quarter of 2021.
It can be making ready to ship 100 million doses to the United States by January after it was awarded $1.6 billion for growing and testing its potential vaccine.
Novavax can be operating a totally enrolled Phase 2b trial in South Africa and a Phase 1/2 continuation in the United States and Australia. Efficacy knowledge from the trials may very well be obtainable early subsequent yr.
primarily based on website supplies www.cnbc.com